Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAD Study of HSK56630 in Healthy Participants
NCT07580794Phase 1Recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HSK56630 (2 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Safety and tolerability of single ascending doses at 8 days. Started Jun 2026; status: recruiting.
02
Drugs
HSK56630
Beyond the preview
Go deeper on NCT07580794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07580794.